Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Biological Treatments in Atopic DermatitisHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseTherapeutic drug monitoring in inflammatory bowel diseaseReview article: anti-adhesion therapies for inflammatory bowel diseaseInfliximab-Related Infusion Reactions: Systematic ReviewVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Use of the tumor necrosis factor-blockers for Crohn's diseaseExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesThiopurines and inflammatory bowel disease: Current evidence and a historical perspectiveSystematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitisIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Review article: dose optimisation of infliximab for acute severe ulcerative colitis.Pharmacokinetic characteristics of therapeutic antibodies.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Combination therapy for inflammatory bowel diseaseTherapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.European evidence-based Consensus on the management of ulcerative colitis: Current management.Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Current status of thiopurine analogues in the treatment in Crohn's disease.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseMethotrexate for Inflammatory Bowel Diseases - New DevelopmentsInfliximab in the treatment of plaque type psoriasis.Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupThe development and assessment of biological treatments for children.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.Infliximab to treat Crohn's disease: an update.Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.Biologics in paediatric Crohn's disease.Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysisCombination therapy for the treatment of Crohn's disease.Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's DiseaseSpecialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis.Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
P2860
Q24185835-F5230AF3-75A9-4DB1-85E0-013C14555802Q26745721-D88346D1-3D3F-4E05-B310-D955B8973EF0Q26777409-862042A3-D12D-4158-9FF6-81EA24375D9EQ26799579-317CC858-18F7-412E-A4A5-19F3F439FB52Q26827444-24539171-6E56-44B8-BB73-B04AFFFDA599Q26852729-5D8EA1FF-D505-44AE-8334-3514E62E9046Q26999705-6B22666F-10EA-4016-B7CD-572144BFCB28Q27013835-3B8628F4-D8D5-4A70-A479-4245B3E8FD9EQ27021612-9C1D5E31-C763-40DD-928B-35EF836EBAA6Q27030762-7442F4F5-FB7D-408C-B8E0-C48A87094011Q28066776-F7806651-D399-4134-839C-467D5E550595Q28079644-0A54CBA5-3077-4D5E-B7B5-F9B2A636531EQ28088683-7EB54758-93EF-4C4A-B10D-8D3BA601C09BQ30235581-AB0A6E12-5FC5-44BA-81B4-449F3894DCA0Q30239077-C28973D0-EC9C-41F2-84AB-4301C96C1670Q30316517-C3398478-E6E4-4BD7-B2E1-E18E7313DB62Q30412650-79868432-174C-4924-A5A9-ECDB3A02FF13Q30995889-EAFFD1C1-7F2D-45DD-9715-CC01F5C03E6BQ33646452-D0DDF0EB-C0A4-45F6-97AF-28E414D1990AQ33874790-4C282FE9-97AC-42A2-8664-98F4E3EC1940Q34025054-A28B35E2-044D-4496-BD32-F4AD0500FE2EQ34047653-3FDF7461-96E4-4519-B1CF-457F2960828EQ34152778-42906912-1E2E-40D0-AC69-B73AEC93F5BBQ34235370-093AB8D5-AC5D-4AD0-A862-B4B97134E075Q34449843-EC8FF134-11DD-42DE-95F1-6669F7973B57Q34518393-5E93D5DB-F0A7-4766-8433-CFF217EF1C6CQ34620291-C819E124-C6C5-4C6A-AA18-85A9B330B041Q35013983-2F40B60D-BECA-4A6F-9A64-3038AB5C1B1AQ35135936-8573B5D4-5FB3-46CA-8092-2342A97F2697Q35193565-C2954498-F22C-4D63-9822-7A569957F63EQ35213972-780B18A0-108B-4CC4-B555-7B0CCFB7D4E7Q35304737-6CF35183-13CA-43B2-BBF1-01F1D8849319Q35547487-6CBD51AF-C089-4F36-A301-560CFF0638E8Q35579308-EFFD2852-0631-477B-B4C2-2CBA000B65B7Q35679414-36C94B13-1369-4287-9535-CFAFA89D152FQ35714202-16AD31C7-4832-42B2-8F02-5D310849DCB9Q35763489-98347F4F-86D4-4ED3-BBA4-ACDF7C14B2D4Q35780904-1AB67697-3DC7-411B-ACBA-9BF877B73BECQ36193973-5A9BC7FF-0E13-4AE8-980D-0455852C810DQ36209653-E8E9C6B7-D6AC-428A-ACC8-4178CB2DFAB2
P2860
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@ast
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@en
type
label
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@ast
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@en
prefLabel
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@ast
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@en
P2093
P2860
P50
P356
P1433
P1476
Effectiveness of concomitant i ...... infliximab in Crohn's disease.
@en
P2093
Filip Baert
Maja Noman
Severine Vermeire
P2860
P304
P356
10.1136/GUT.2006.099978
P407
P577
2007-01-17T00:00:00Z